ClinicalTrials.gg
RecruitingNCT07048522Updated Sep 14, 2026

Perioperative Intravenous Nimodipine Trial

An interventional study of Nimodipine and Isotonic Saline in Colectomy, Open Surgery and Pain, sponsored by University of Ioannina. Recruiting at 1 site in Greece. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-14.

Sponsored by University of Ioannina · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 38 studies in Pain with a site in Greece — 9 open to participants now, 9 under way, none of them phase 3. Pain · Greece.

Planned enrollment
24th of 31
40 · median 70
Started
2025
with 4 others
No phase
21 of 38
8 open now
Registered
32nd of 38
by date

Among the 38 studies in Pain with a site in Greece, this one is the 24th largest by planned enrollment of the 31 interventional ones that give a count, is one of 5 that started in 2025, is one of 21 with no phase, and was the 32nd registered.

Pain

10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.

Browse Pain studies →

Open to participants now

9 of the 38 studies in Pain with a site in Greece are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Greece have not opened yet or have stopped. Only those recruiting at a site in Greece →

Who these studies take

Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Pain with a site in Greece, or all of them as a file.
02

Study summary

The role of perioperative IV administration of nimodipine, an L-type calcium channel antagonist which is capable of crossing the blood-brain barrier, on peri-operative opioid and anesthetics requirements, pain intensity, opioid-related side effects and early postoperative bowel mobility in patients undergoing surgical treatment for bowel cancer with open radical colectomy remains scarcely explored. A prospective double-blind, randomized controlled trial investigating the effect of perioperative IV administration of nimodipine in patients undergoing open colectomy for cancer treatment is therefore conducted.

Read the detailed description

Background with aim: Acute postoperative pain is still of major clinical concern for a large number of patients undergoing surgery worldwide. Despite advances in pain management strategies, many patients continue to suffer from moderate-to-severe pain during the early postoperative period, while opioids are still largely over-prescribed. Not effectively and especially unrelieved pain can result in decreased patient satisfaction, increased morbidity, prolonged hospital length-of-stay and increased risk of persistent pain. Furthermore, effective treatment of acute postoperative pain using opioid analgesics remains the core treatment for postoperative pain. Although the potential benefits of opioid therapy for acute pain lead to a short-term pain control there are several potential severe side-effects associated with opioid use which may outweigh the benefits including sedation, nausea, vomiting, constipation especially in bowel surgery, and the risk of long-term use. Although various non-opioid drugs have been investigated over the past decades, information regarding L-type calcium channel blockers in acute postoperative pain is limited. In this respect, the perioperative use of nimodipine, a drug which furthermore crosses the blood-brain barrier and has direct effects on the Central Nernous System (CNS) could potentiate the effects of opioid analgesia and intraoperative anesthetic requirements, providing improved analgesia and potentially reduce for opioids in the perioperative period. Therefore, the investigators decided to carry out the present study with the aim to examine the analgesic efficacy and safety of perioperatively administered IV nimodipine in patients undergoing open colectomy on perioperative opioid and anesthetic consumption, pain intensity, opioid-related side effects and early postoperative bowel mobility.

Method: A power analysis based on a previous preliminary study using IV nimodipine for medium risk general surgery (open cholecystectomy) showed that 9 patients would provide a power greater than 0.9 (α = 0.05) for detection of differences of pain scores and cumulative opioid consumption over time (up to 48 h). Therefore, 40 patients undergoing open colectomy will be included in this prospective, randomized, double-blind, controlled trial with two arms: an intervention arm (IV nimodipine 2 mg/h [10 ml/h] starting 1 h prior to surgery and continuing until 24 h after the end of the procedure) and a control arm (isotonic saline 10 ml/h starting 1 h prior to surgery and continuing until 24 h after the end of the procedure). The study is approved by the local hospital scientific board (#18-4_2024-12-05).

Hypothesis: The investigators hypothesize that perioperative intravenous administration of nimodipine, an L-type calcium channel antagonist, will be effective in reducing intraoperative anesthetic requirements, as well as intra- and postoperative opioid requirements, as well as postoperative pain intensity and opioid-related side effects.

03

Conditions studied

  • Colectomy
  • Open Surgery
  • Pain
  • Pain, Postoperative
  • Pain, Acute
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients scheduled for open surgical treatment of bowel cancer at the General Hospital of Patra

Exclusion criteria

Exclusion Criteria:

  • Age \< 18 years, > 75 years
  • (ASA) physical status > III
  • Allergy to nimodipine
  • Inability to provide
  • Known severe renal insufficiency
  • Known severe bradyarrhythmia
  • Daily opioid consumption the last 7 days before surgery
  • Pain intensity assessed using the Numerical Rating Scale (NRS; 0-10), with scores greater than 5 reported on more than half of the days during the past month.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Nimodipine

    Prepared (coded) by the pharmacy 50 ml solutions of nimodipine (2 mg/10 ml) with blinded 50 ml syringes will be used in each patient.

    Drug: Nimodipine

  • Placebo comparator
    Isotonic saline

    Prepared (coded) by the pharmacy 50 ml solutions with blinded 50 ml syringes of isotonic saline will be used in each patient.

    Drug: Isotonic Saline

Interventions

  • A continuous dose of 2 mg/h (10 ml/h) of nimodipine solution will be administered continuously one (1) h prior to start of operation until 24 h after the end of the procedure.

  • DrugIsotonic Saline

    A continuous dose of 10 ml/h of normal saline solution will be administered continuously one (1) h prior to start of operation until 24 h after the end of the procedure.

06

What researchers measure

Primary outcomes

  1. Intraoperative Remifentanil Consumption

    Remifentanil will be administered intraoperatively based on qNOX (quantum NOXious stimulus index) levels, which will be maintained between 40 and 60. qNOX values below 40 will prompt a reduction in remifentanil dosing, while values above 60 will prompt an increase, in order to optimize analgesia.

    Time frame: Intraoperative period, defined as the time (in minutes) from induction of general anesthesia to extubation.

  2. Intraoperative propofol consumption

    Propofol will be administered intraoperatively based on BIS (Bispectral Index) and qCON (quantum Consciousness Index) values, which will be maintained between 40 and 60. BIS or qCON values below 40 will prompt a reduction in propofol dosing, while values above 60 will prompt an increase, in order to maintain appropriate depth of anesthesia.

    Time frame: Intraoperative period, defined as the time (in minutes) from induction of general anesthesia to extubation.

  3. Cumulative opioid consumption within 0 to 72 hours postoperatively

    Cumulative morphine consumption (mg) during the first 72 hours after arrival at the Post Anesthesia Care Unit (PACU). During the first hour in the PACU, morphine will be administered using a titration method. Following transfer to the surgical ward, a patient-controlled analgesia (PCA) device will be used to monitor morphine consumption. Cumulative opioid use will be recorded at specific time points: 3, 6, 12, 18, 24, 30, 36, 48, 60, and 72 hours postoperatively.

    Time frame: From Post Anesthesia Care Unit (PACU) admission (time zero) to 72 hours postoperatively.

Secondary outcomes

  1. Pain intensity at rest

    Pain intensity at rest will be assessed using the Numerical Rating Scale (NRS; 0-10), starting upon arrival at the Post Anesthesia Care Unit (PACU) and continuing at the following postoperative time points on the ward: 3, 6, 12, 18, 24, 30, 36, 48, 60, and 72 hours.

    Time frame: From Post Anesthesia Care Unit (PACU) admission (time zero) to 72 hours postoperatively.

  2. Pain intensity during coughing

    Pain intensity during coughing will be assessed using the Numerical Rating Scale (NRS; 0-10), beginning upon arrival at the Post Anesthesia Care Unit (PACU) and at the following postoperative time points on the ward: 3, 6, 12, 18, 24, 30, 36, 48, 60, and 72 hours.

    Time frame: From Post Anesthesia Care Unit (PACU) admission (time zero) to 72 hours postoperatively.

  3. Opioid related sedation

    Number of participants with postoperative sedation assessed using the Ramsay Sedation Scale (range: 1 = anxious/agitated to 6 = no response to stimulus).

    Time frame: From Post Anesthesia Care Unit (PACU) admission (time zero) to 72 hours postoperatively.

  4. Opioid related pruritus

    Number of participants with documented pruritus related to opioid use, recorded as a binary outcome variable (yes/no).

    Time frame: From Post Anesthesia Care Unit (PACU) admission (time zero) to 72 hours postoperatively.

  5. Postoperative nausea and/or vomiting (PONV)

    Number of participants with documented postoperative episodes of nausea and/or vomiting, recorded as a binary outcome variable (yes/no).

    Time frame: From Post Anesthesia Care Unit (PACU) admission (time zero) to 72 hours postoperatively.

  6. Time to first signs of bowel mobilization

    Time (in hours) from the end of surgery to the first documented sign of bowel function, defined as either the first bowel sounds on auscultation or the first passage of flatus. Assessment will take place in the surgical ward at the following postoperative time points: 24, 30, 36, 42, 48, 54, 60, 66, 72, 78, 84, and 90 hours, or until hospital discharge, whichever comes first.

    Time frame: From end of surgery to 90 hours postoperatively or until hospital discharge, whichever comes first.

  7. Length of stay (LOS)

    Total duration of hospitalization, measured in days from admission to discharge.

    Time frame: Duration of hospitalization, from the day of admission to the day of discharge (up to 30 days).

07

Study locations

1 of 1 sites recruiting
  • St. Andrews General Hospital of Patras, GREECE
    Pátrai, Achaea 263 32, Greece
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — The data will be shared upon reasonable request by other researchers

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Dec 2026, 19 months after the start.

Of 3,749 non-industry interventional studies with no phase under Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 23. This study's planned 19 months is above that.

Counting every sponsor, half of 3,848 studies reached it within 10 months; a quarter within 4 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2025
First posted
Jul 2, 2025
StartActual
May 19, 2025
Primary completionEst.
Dec 19, 2026
CompletionEst.
Feb 15, 2027
Last update
Sep 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07048522
Lead sponsor
University of Ioannina
Responsible party
Petros Tzimas (Professor of Anesthesiology, University of Ioannina) — Principal investigator
First posted
Jul 2, 2025
Start date
May 19, 2025
Primary completion
Dec 19, 2026 (estimated)
Completion
Feb 15, 2027 (estimated)
Last update
Sep 14, 2026

Study contacts

Maria-Theodora Filou, MD
Contact
marilizafilou@gmail.com
00306948127570
Ourania Patroni, MD
Contact
patronirania@gmail.com
00302613601673
Petros Tzimas, MD, PhD
principal investigator · University of Ioannina, Greece

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nimodipine

Start the discussion